Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 13, 2007

LOBBYING REPORT

Lobbying Disclosure Act of	1995 (Section 5	5) - All Filers A	re Required To	Complete This Page

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

1. Registrant Name: STUNTZ DAVIS & STAFFIER 555 ELEVENTH ST NW # 550, WASHINGTON, DC 20004 3. Principal place of business (if different from line 2): 4. Contact Name: RANDALL E. DAVIS Telephone: 2026386588 E-mail (optional): erodriguez@sdsatty.com Senate ID #: 37141-164 House ID #: 7. Client Name: Self PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA TYPE OF REPORT 8. Year 2006 Midyear (January 1 - June 30): OR Year End (July 1 - December 31): X 9. Check if this filing amends a previously filed version of this report: 10. Check if this is a Termination Report:

=> Termination Date: 11. No Lobbying Activity: INCOME OR EXPENSES Complete Either Line 12 OR Line 13 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000: X \$10,000 or more: => Income (nearest \$20,000);_ Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000: -\$10,000 or more: => Expenses (nearest \$20,000); 14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options.

Page 1

Registrant Name: STUNTZ DAVIS & STAFFIER Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: PHA (one per page)
- 16. Specific lobbying issues:

Draft proposals to reauthorize the Prescription Drug Benefit User Fee Act. Medicare policies regarding noninterference with private contracts between drug companies and pharmaceutical benefit providers. Drug reimportation amendments to FY07 Agriculture appropriations bill, H.R. 5384, and FY07 Homeland Security Appropriations bill, H.R. 5441.

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DAVIS, RANDALL E. Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 13, 2007

Printed Name and Title: RANDALL E. DAVIS, PRESIDENT -

Page 2